ALZHEIMER’S DISEASE AND RELATED DEMENTIAS - IV A DECADE OF PET FOR AMYLOID IMAGING: INSIGHTS FROM REAL-WORLD EVIDENCE - Supporting Alzheimer’s Diagnosis

Sep 29, 2026

Upload by ahduag

Positron emission tomography (PET) with florbetaben (FBB) was approved in the US in 2014 to image amyloid plaques in individuals evaluated for Alzheimer’s disease (AD). This work summarizes real-world evidence of FBB’s clinical and research use, including visual and quantitative assessment of amyloid PET images. It evaluates the efficacy of the approved visual assessment in routine practice and reports performance across 15 quantitative pipelines, showing sustained accurate reading by experts and naïve readers over time. Quantification using 510(k)-approved software demonstrates robust, homogeneous accuracy that supports treatment selection and monitoring.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Study Objectives and Scope

Visual Assessment in Routine Practice

Quantitative Pipelines and Reliability

Implications for Patient Selection and Treatment Monitoring

Innovation in Aging, 2025, Vol. 9, No. S2 939 reliable, and available tool in the diagnostic pathway of AD, as indicated within the Alzheimer’s Association’s (AA) Updated Criteria for AD Diagnosis and Staging and the AA/Society for Nuclear Medicine’s Appropriate Use Criteria for PET. With the approval of amyloid-targeting therapies, standardized quantification approaches, such as the Centiloid scale, are becoming increasingly important for patient selection and treatment monitoring. SESSION 7415 (POSTER) Abstract citation ID: igaf122.3172 ALZHEIMER’S DISEASE AND RELATED DEMENTIAS IV A DECADE OF PET FOR AMYLOID IMAGING: INSIGHTS FROM REAL-WORLD EVIDENCE SUPPORTING ALZHEIMER’S DIAGNOSIS Margaret Cadden1, Samantha Rossano1, Brittany Watson1, Marianne Chapleau1, Santiago Bullich2, Andrew Stephens2, Norman Koglin2, and Aleksandar Jovalekic2, 1. Life Molecular Imaging, Boston, Massachusetts, United States, 2. Life Molecular Imaging, Berlin, Brandenburg, Germany Positron emission tomography (PET) scanning with florbetaben (FBB) was approved in the US in 2014 after validation in histopathological studies for imaging of amyloid plaques in individuals being evaluated for Alzheimer’s disease (AD). The current abstract incorporates real-world evidence of FBB’s clinical and research use, including results from visual and quantitative assessment of amyloid PET images. The objectives of this work included 1) Evaluating the efficacy of the approved visual assessment method in the routine clinical practice and 2) Presenting results of 15 quantitative pipelines to underscore reliability and added value of quantification. The studies’ results confirmed that, both experts and naïve readers accurately assess FBB PET scansand maintain these abilities over time (correct assessments: 96% at baseline and 92% at 6 months follow-up). Quantitative methods, including 510(k) approved software, consistently demonstrated robust and homogeneous performance (accuracy 96.4±1.1%), offering valuable support for visual assessments. Since its approval, visual assessment and quantification of FBB images have undergone additional validation across diverse settings including clinical routine. FBB PET imaging is a validated,

FAQs

How do visual and quantitative methods perform over time?

Experts and naïve readers maintain high accuracy at baseline (96%) and at 6 months follow-up (92%), while quantitative methods using 510(k)-approved software show robust and homogeneous performance (accuracy 96.4±1.1%).

Sep 29, 2026

Upload by ahduag